Linagliptin
- Level
- Commodity
- Parent
- 51183300
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51183301This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X29ZEJ4R2. European Medicines Agency schedules Linagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31340. Linagliptin generally arises in the molecular formula C25H28N8O2. The term LINAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 1, 2009, list 61.) As of Q4 2014, LINAGLIPTIN remains US FDA's Preferred Term for this commodity. Linagliptin bears US NLM identifiers UMLS ID C2746078 and NCI Concept Code C83887. SMILES: CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.
Same parent
Under 51183300 · 9Activities that produce or sell this
KBLI · 8Inherited from family 51180000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.